Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.

CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates ...

The CDC intends to transfer more than 160 macaques to Born Free USA, a nonprofit that runs a large primate sanctuary in Texas ...

At MIT, research has shrunk 10% from a year ago, and the school expects a persistent drop in graduate admissions.

Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets ...

Leaders want the next FDA commissioner to be someone who can rebuild trust, focus on food policy, and drive drug-approval ...

Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a ...

Despite rising concern about the hantavirus outbreak on a cruise ship, two CDC doctors say the risk to the public remains low ...

The authors have each served as director of the Centers for Disease Control and Prevention. One misguided narrative is that the CDC should focus only on a “core mission” of combatting infectious ...

Kyle Diamantas, the acting commissioner of the FDA, is expected to be a drama-free, stabilizing caretaker at the top of the ...

The next FDA leader, how the CDC is responding to hantavirus, and more health news from Morning Rounds ...

Arriving in the isolation ward of a biocontainment hospital is an unsettling, scary experience. In 2014, I spent 19 days in ...